Inibidores de Jak no tratamento da psoríase: eficácia, segurança e efeitos adversos

• Autores: Raiane Cardanha de Lima, Rafaela Lambert Assis Sousa, Larissa Becker de Godoy, Larissa Fernandes de Andrade, Camilly Canela Tregancini, Ingrid de Oliveira Silva, Bruna Vanzela dos Santos, Carolina Soraya de Proença Dantas
• Localización: Cuadernos de Educación y Desarrollo, ISSN-e 1989-4155, Vol. 16, Nº. Extra 2, 2024
• Idioma: inglés
• DOI: 10.55905/cuadv16n2-ed.esp.051
• Enlaces
  • Texto completo
• Resumen

  • Objetivo: Avaliar os inibidores de JAK no tratamento da psoríase, considerando seus benefícios e riscos. Métodos: A revisão seguiu as diretrizes do Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) realizando buscas nas bases de dados PubMed, Scielo, Uptodate e Word Wide Science.org, selecionando estudos que abordaram os inibidores de JAK como proposta terapêutica. Resultados: Foram analisados artigos publicados entre 2013 a 2023, sendo identificados 539 artigos, dos quais foram aplicados critérios de elegibilidade, análise e exclusão sendo incluídos 30 artigos na revisão. Os critérios de inclusão abordaram o mecanismo de ação, eficácia, segurança e eventos adversos dos Inibidores da JAK no tratamento da psoríase. Conclusão: Apesar da complexidade da via JAK/STAT trazer riscos de toxicidade e desafios a escolha terapêutica, estudos clínicos e meta-análises avaliaram um avanço no tratamento da psoríase e outras doenças autoimunes dermatológicas, devendo criar abordagens personalizadas para cada paciente, minimizando efeitos colaterais.

• Referencias bibliográficas
  • CAIAZZO, G. et al. The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of Clinical Medicine, v. 12, n. 8, p. 2865, 1...
  • CALAUTTI, E.; et al. Psoriasis: A STAT3-Centric View. International Journal of Molecular Sciences, v. 19, n. 1, p. 171, 6 janeiro 2018.
  • DAMSKY, W., et al. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. n.4, vol.76, p 736-744, 2017.
  • DI LERNIA, V.; BARDAZZI, F. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis,...
  • GARCIA, F.G.; et al. A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis. Frontiers in Medicina, v.9, p. 1-10, fevereiro...
  • GOODERHAM, M.J., et al. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis, Skin Therapy Letter, v....
  • HOWELL, M. D.; et al. Targeting the Janus Kinase Family in Autoimmune Skin Diseases. Frontiers in Immunology, v. 10, 9 outubro 2019.
  • KASHETSKY, N., et al. Utilization of Topical Ruxolitinib in Dermatology: A Review, Skin Therapy Letter, v. 28, n.3, junho 2023.
  • KLEIN, B.; et al. JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results...
  • KOTYLA, P. et al. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? International...
  • KVIST-HANSEN, A.; et al. Systemic Treatment of Psoriasis with JAK Inhibitors: A Review. Dermatology and Therapy, v. 10, n. 1, p. 29–42, 1...
  • MARUSHCHAK, O. et al. Review on Novel Oral Therapies for Psoriasis. The Journal of clinical and aesthetic dermatology, v. 14, n. 12, p. 55–63,...
  • MIOT, A. H. et al. JAK‐STAT pathway inhibitors in dermatology. An Bras Dermatol. n. 5, vol. 98, p. 656-77. 2023.
  • MORELLI, M. et al. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications...
  • PAGE, K.M., et al. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque...
  • ROSKOSKI, R. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacological Research....
  • RUSIÑOL, L.; et al. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International Journal of Molecular Sciences, v. 24, n. 4, p....
  • RUSSELL, M. et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Annals of the Rheumatic Diseases,...
  • SADEGHI, S.; et al. Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review...
  • SAMUEL, C. et al. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. Dermatogy and Therapy,...
  • SARABINA, S. et al. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis....
  • SHAWKY, A. M. et al. A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, v. 14, n. 5, p. 1001, 1 maio 2022.
  • SIDERIS, N. et al. Under Development JAK Inhibitors for Dermatologic Diseases. Mediterr J Rheumatol. n.1, vol.31, p 137-144.2020.
  • SMITH, P. et al. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics, v. 13, n. 7, p. 1044, 8 julho 2021.
  • SOLIMANI, F., et al. Emerging Topical And Systemic JAK Inhibitors ins Dermatology. Front. Immunol. vol. 10. 2019.
  • STROBER, B. et al. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across...
  • SUNZINI, F.; et al. JAK inhibitors and infections risk: focus on herpes zoster. Therapeutic Advances in Musculoskeletal Disease, v. 12, 29...
  • VIEIRA-GRANJA, B.; et al. Janus Kinase inhibitors in dermatology: a review. Portuguese Journal of Dermatology and Venereology, v. 81, n. 1,...
  • WOLK, R., et al. Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. Journal...
  • XU, Q.; et al. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network...